PhaseBio Pharmaceuticals, Inc.

106 articles about PhaseBio Pharmaceuticals, Inc.

• PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

  3/11/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a commercial scale supply agreement for the production of bentracimab,

• PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences

  2/26/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor conferences.

•  PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021

  2/24/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host a virtual Investor and Analyst Day on March 15, 2021 from 12:00 p.m. to 2:00 p.m. ET.

• PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

  1/28/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that in conjunction with its financing and co-development partner for the European Union and China, SFJ Pharmaceuticals, PhaseBio has expanded its pivotal Phase 3 REVERSE-IT trial for its lead product candidate bentracimab into the European Union,

• PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress

  1/27/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of data from a Phase 1b/2a pilot study highlighting three patients who received pemziviptadil (PB1046)

• PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results

  11/12/2020

  Expanded pivotal Phase 3 REVERSE-IT trial of product candidate bentracimab (PB2452) for reversal of antiplatelet effects of ticagrelor into Canada and dosed first patients outside the United States Resuming enrollment in ongoing Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension

• PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

  11/11/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the Stifel

• PhaseBio Provides Pemziviptadil (PB1046) Program Update

  10/23/2020

  VANGARD trial discontinued due to evolving COVID-19 treatment landscape, recent feedback from FDA regarding regulatory and development path, and interim analysis of trial data Enrollment expected to resume for ongoing Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH)

• PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor

  10/6/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has expanded its pivotal Phase 3 REVERSE-IT trial for its lead product candidate bentracimab

• PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the upcoming H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15, at 12:00

• PhaseBio to Present at the William Blair Biotech Focus Conference 2020

  8/3/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced that Chief Executive Officer Jonathan P. Mow and other members of the management team will participate in a fireside chat at the upcoming William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2:00 p.m. EDT.

• 

  Clinical Catch-Up: July 13-17

  7/20/2020

  It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.

• DSG Supports PhaseBio Pharmaceuticals with Unified Clinical Trial Software Platform for COVID-19 Trial

  7/17/2020

  DSG, Inc. , a global leader of eClinical software solutions and services for the life sciences industry has successfully launched a COVID-19 study with PhaseBio Pharmaceuticals for its potentially pivotal clinical trial evaluating PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS). Understanding the urgent nature

• 

  Biopharma Update on the Novel Coronavirus: July 17

  7/17/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.

• PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

  7/16/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

• PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

  5/27/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

• PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights

  5/12/2020

  PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, reported financial results from the first quarter ending March 31, 2020 and provided an update on corporate activities.

• PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights

  3/30/2020

  PhaseBio today reported financial results for the fourth quarter and full-year ended December 31, 2019, and provided an update on corporate activities.

• PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference

  2/26/2020

  PhaseBio Pharmaceuticals, Inc. announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, at 10:40 a.m. EST in Boston.

• PhaseBio Appoints Alex C. Sapir to Board of Directors

  2/13/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Alex C. Sapir to its board of directors.